CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 697 enrolled
Drug / intervention
Peginterferon alfa-2a +1 morebiological
Likely dose
Ribavirin 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02557646
NCT02557646N/ACompleted
CompareCT.gov

An Observational Study to Assess the Effect of Cumulative Ribavirin Dose in Participants With Chronic Hepatitis C

Hoffmann-La Roche·observational·Posted Sep 23, 2015·Updated Mar 28, 2016

In Brief

An observational study evaluating Peginterferon alfa-2a and Ribavirin for Hepatitis C, Chronic. Completed, enrolled 697 participants across 27 sites.

Detailed Summary

The purpose of this open-label, non-randomized, single-arm, multicentre observational study is to investigate the influence of the cumulative dose (total administered dose/ planned dose) of ribavirin on the sustained virologic response (SVR) in participants who have been receiving combination therapy with pegylated interferon alfa-2a (Pegasys) and ribavirin (Copegus).

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C, Chronic
CountriesHungary
Collaborators--

Timeline

N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 23, 2015
Enrollment StartMay 1, 2009
Primary CompletionMar 1, 2014
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 10.8 years ago

Interventions

Peginterferon alfa-2abiological

Participants received pegylated interferon subcutaneous injection in accordance with current guidelines and SPCs.P

Ribavirindrug

Participants received ribavirin 200 mg film-coated tablet in accordance with current guidelines and SPCs.